Could one antibiotic replace two for chemo fevers? major trial launches
NCT ID NCT07483736
First seen Mar 25, 2026 · Last updated Jun 12, 2026 · Updated 16 times
Summary
This study compares a single antibiotic (amoxicillin-clavulanate) against the standard two-drug combination (amoxicillin-clavulanate plus ciprofloxacin) for treating fever caused by chemotherapy in adults with certain blood cancers. The goal is to see if the simpler treatment works just as well, while reducing side effects and antibiotic resistance. About 1,500 participants will be randomly assigned to one of the two treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Jacques Coeur
Bourges, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH Poissy Saint-Germain-en-Laye
Poissy, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH de BRIVE LA GAILLARDE
Brive-la-Gaillarde, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH de Perigueux
Périgueux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH de SAINT NAZAIRE
Saint-Nazaire, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH de SAUMUR
Saumur, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH de Valence
Valence, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH de Versailles
Le Chesnay, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Caen-Normandie
Caen, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU d'ORLEANS
Orléans, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de SAINT-ETIENNE
Saint-Priest-en-Jarez, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Groupe Hospitalier Haute Saône Vesoul
Vesoul, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Necker Enfants Malade
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Saint Louis
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital de La Pitie Salpetriere
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Curie
Saint-Cloud, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.